Table 2.

Combinatorial approach towards management of influenza infections.

Drug combinations	Influenza subtype	Activity spectrum	Experimental condition	Ref.
Double drug combination
Rimantadine + Ribavirin	H1N1 H3N2	Virus yield inhibition	In vitro	(Hayden et al., 1980)
	H1N1 H3N2 B	Virus yield inhibition	In vitro	(Hayden et al., 1984)
Amantadine + Ribavirin	H5N1	Virus yield inhibition	In vitro	(Smee et al., 2009)
	H1N1	Virus yield inhibition	In vitro	(Nguyen et al., 2010)
	H5N1	Virus yield inhibition	In vivo	(Smee et al., 2009)
Zanamivir + Rimantadine	H1N1 H3N2	Virus yield inhibition	In vitro	(Govorkova et al., 2004)
Oseltamivir carboxylate + Amantadine	H1N1 H3N2 H5N1	Virus yield inhibition	In vitro	(Ilyushina et al., 2006; Nguyen et al., 2010)
	H1N1 H3N2 H5N1	Virus yield inhibition	In vivo	(Masihi et al., 2007; Smee et al., 2009)
Oseltamivir carboxylate + Ribavirin	H1N1	Virus yield inhibition	In vitro	(Nguyen et al., 2010)
	H1N1 B H5N1	Virus yield inhibition	In vivo	(Smee et al., 2006; Smee et al., 2009)
Oseltamivir + Favipiravir	H1N1 H3N2 H5N1	Virus yield inhibition	In vivo	(Smee et al., 2010)
Tripple drug combination
Oseltamivir carboxylate + Amantadine + Ribavirin	H1N1 H3N2 H5N1	Virus yield inhibition	In vitro	(Nguyen et al., 2009; Nguyen et al., 2010)